Novo Nordisk A/S’s metabolic monster, semaglutide, is already under review at the US Food and Drug Administration to add heart failure to its litany of approved indications. Data presented at the weekend will add impetus to the argument for its approval, and intriguingly, the STEP-HFpEF DM study suggests that the GLP-1 agonist could treat heart failure over and above its weight loss effects alone.
Semaglutide Might Treat Heart Failure Directly
Novo Nordisk’s product’s reputation as a wonder drug grows as new data suggest it might be disease-modifying in heart failure.
